<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04528355</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY20070105</org_study_id>
    <nct_id>NCT04528355</nct_id>
  </id_info>
  <brief_title>Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC</brief_title>
  <acronym>PRO-RIC</acronym>
  <official_title>A Prospective Outcomes Study of Pediatric and Adult Patients With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation With a Reduced-Intensity Conditioning Regimen (PRO-RIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paul Szabolcs</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a data collection study that will examine the general diagnostic and treatment data&#xD;
      associated with the reduced-intensity chemotherapy-based regimen paired with simple&#xD;
      alemtuzumab dosing strata designed to prevented graft failure and to aid in immune&#xD;
      reconstitution following hematopoietic stem cell transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hematopoietic stem cell transplantation (HSCT) from a healthy donor can cure or alleviate a&#xD;
      broad spectrum of non-malignant disorders (NMD). Although reduced-intensity conditioning&#xD;
      (RIC) regimens promise decreased treatment-related morbidity and mortality, graft failure and&#xD;
      infections are limiting the use of RIC in chemotherapy-naive patients. Dr. Szabolcs have&#xD;
      completed several trials to evaluate a novel RIC regimen of alemtuzumab, hydroxyurea,&#xD;
      fludarabine, melphalan, and thiotepa. The last trial at UPMC Children's Hospital of&#xD;
      Pittsburgh of a highly effective and biologically rational chemotherapy-based RIC regimen&#xD;
      paired with simple alemtuzumab dosing strata was tested and resulted in outstanding survival&#xD;
      and remarkably low rates of graft failure. The favorable outcome described may serve as a&#xD;
      toxicity and efficacy reference for emerging gene therapy strategies as well.&#xD;
&#xD;
      This prospective collection of clinical data will allow the investigators to further assess&#xD;
      engraftment, GVHD, immunosuppressant use and overall survival in this patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of acute graft versus host disease (GVHD)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>grades 3-4, chronic extensive GVHD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival after HSCT</measure>
    <time_frame>up to 5 years</time_frame>
    <description>review of the existing medical records to check on the participant's survival status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe degree of engraftment, based upon chimerism data</measure>
    <time_frame>up to 5 years</time_frame>
    <description>review of chimerism test results in the existing medical records to check on degree of donor engraftment measured by the percentage of donor-derived blood cells in the HSCT recipient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe probability to discontinue systemic immunosuppression medications</measure>
    <time_frame>by 6, 9, and 12 months post-HSCT</time_frame>
    <description>review of the existing medical records to check on the participant's current medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the tempo of immune reconstitution</measure>
    <time_frame>over the first year post transplant</time_frame>
    <description>review of the various test results in existing medical records to check on the participant's immune system recovery rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the use of donor leukocyte infusion (DLI)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>review of the existing medical records to check on the participant's need for DLI</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Primary Immunodeficiency (PID)</condition>
  <condition>Congenital Bone Marrow Failure Syndromes</condition>
  <condition>Inherited Metabolic Disorders (IMD)</condition>
  <condition>Hereditary Anemias</condition>
  <condition>Inflammatory Conditions</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>data collection</intervention_name>
    <description>Study subjects will receive alemtuzumab, melphalan, thiotepa, fludarabine and hydroxyurea-based, reduced-intensity conditioning regimen in accordance with clinical practice at UPMC Children's Hospital of Pittsburgh at the discretion of the treating physician. Medical data will be abstracted from subject's medical charts once the patient signs the informed consent.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or&#xD;
        Peripheral Blood Stem Cell Transplantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient, parent, or legal guardian must have given written informed consent.&#xD;
&#xD;
          2. Patient must be 2 months to 60 years (inclusive) of age at time of consent for all&#xD;
             diagnoses.&#xD;
&#xD;
          3. Patients should have a non-malignant disorder amenable to treatment by stem cell&#xD;
             transplantation, including but not limited to the following:&#xD;
&#xD;
             A. Primary Immunodeficiency Syndromes&#xD;
&#xD;
               -  Severe Combined Immune Deficiency (SCID) with NK cell activity&#xD;
&#xD;
               -  Omenn Syndrome&#xD;
&#xD;
               -  Bare Lymphocyte Syndrome (BLS)&#xD;
&#xD;
               -  Combined Immune Deficiency (CID) syndromes&#xD;
&#xD;
               -  Combined Variable Immune Deficiency (CVID) syndrome&#xD;
&#xD;
               -  Wiskott-Aldrich Syndrome&#xD;
&#xD;
               -  Leukocyte adhesion deficiency&#xD;
&#xD;
               -  Chronic granulomatous disease (CGD)&#xD;
&#xD;
               -  Hyper IgM (XHIM) syndrome&#xD;
&#xD;
               -  IPEX syndrome&#xD;
&#xD;
               -  Chediak-Higashi Syndrome&#xD;
&#xD;
               -  Autoimmune Lymphoproliferative Syndrome (ALPS)&#xD;
&#xD;
               -  Hemophagocytic Lymphohistiocytosis (HLH) syndromes&#xD;
&#xD;
               -  Lymphocyte Signaling defects&#xD;
&#xD;
             B. Congenital Bone Marrow Failure Syndromes&#xD;
&#xD;
               -  Congenital Amegakaryocytic Thrombocytopenia (CAMT)&#xD;
&#xD;
               -  Osteopetrosis&#xD;
&#xD;
             C. Inherited Metabolic Disorders (IMD)&#xD;
&#xD;
               -  Mucopolysaccharidoses&#xD;
&#xD;
                    -  Hurler syndrome (MPS I)&#xD;
&#xD;
                    -  Hunter syndrome (MPS II)&#xD;
&#xD;
               -  Leukodystrophies&#xD;
&#xD;
                    -  Krabbe Disease, also known as globoid cell leukodystrophy&#xD;
&#xD;
                    -  Metachromatic leukodystrophy (MLD)&#xD;
&#xD;
                    -  X-linked adrenoleukodystrophy (ALD)&#xD;
&#xD;
               -  Other inherited metabolic disorders&#xD;
&#xD;
                    -  Alpha Mannosidosis&#xD;
&#xD;
                    -  Gaucher Disease&#xD;
&#xD;
                    -  Other inheritable metabolic diseases where HSCT may be beneficial&#xD;
&#xD;
             D. Hereditary Anemias&#xD;
&#xD;
               -  Thalassemia major&#xD;
&#xD;
               -  Sickle cell disease (SCD)&#xD;
&#xD;
               -  Diamond Blackfan Anemia (DBA)&#xD;
&#xD;
             E. Inflammatory Conditions&#xD;
&#xD;
               -  Crohn's Disease or Inflammatory Bowel Disease&#xD;
&#xD;
               -  IPEX or IPEX-like Syndromes&#xD;
&#xD;
               -  Rheumatoid Arthritis&#xD;
&#xD;
               -  Other inflammatory conditions where HSCT may be beneficial&#xD;
&#xD;
          4. Subjects receive either umbilical cord blood, bone marrow, or peripheral blood stem&#xD;
             cell transplant with an alemtuzumab, melphalan, thiotepa, fludarabine and&#xD;
             hydroxyurea-based, reduced-intensity conditioning regimen, according to clinical&#xD;
             practice at UPMC Children's Hospital of Pittsburgh.&#xD;
&#xD;
        There are no exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Szabolcs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UPMC Children's Hospital of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Szabolcs, MD</last_name>
    <phone>412-692-5427</phone>
    <email>paul.szabolcs@chp.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shawna McIntyre, RN</last_name>
    <phone>412-692-5552</phone>
    <email>mcintyresm@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawna McIntyre, RN</last_name>
      <phone>412-692-5552</phone>
      <email>mcintyresm@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jessie Barnum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Craig Byersdorfer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Escolar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Stenger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Randy Windreich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Paul Szabolcs</investigator_full_name>
    <investigator_title>Chief, BMT-CT at CHP of UPMC and Professor of Pediatrics and Immunology, University of Pittsburgh</investigator_title>
  </responsible_party>
  <keyword>Severe Combined Immune Deficiency (SCID) with NK cell activity</keyword>
  <keyword>Omenn Syndrome</keyword>
  <keyword>Bare Lymphocyte Syndrome (BLS)</keyword>
  <keyword>Combined Immune Deficiency (CID) syndromes</keyword>
  <keyword>Wiskott-Aldrich Syndrome</keyword>
  <keyword>Leukocyte adhesion deficiency</keyword>
  <keyword>Chronic granulomatous disease (CGD)</keyword>
  <keyword>Hyper IgM (XHIM) syndrome</keyword>
  <keyword>IPEX syndrome</keyword>
  <keyword>Chediak-Higashi Syndrome</keyword>
  <keyword>Autoimmune Lymphoproliferative Syndrome (ALPS)</keyword>
  <keyword>Hemophagocytic Lymphohistiocytosis (HLH) syndromes</keyword>
  <keyword>Lymphocyte Signaling defects</keyword>
  <keyword>Congenital Amegakaryocytic Thrombocytopenia (CAMT)</keyword>
  <keyword>Osteopetrosis</keyword>
  <keyword>Hurler syndrome (MPS I)</keyword>
  <keyword>Hurler syndrome (MPS II)</keyword>
  <keyword>Krabbe Disease, also known as Globoid Cell Leukodystrophy</keyword>
  <keyword>Metachromatic leukodystrophy (MLD)</keyword>
  <keyword>X-linked adrenoleukodystrophy (ALD)</keyword>
  <keyword>Alpha Mannosidosis</keyword>
  <keyword>Gaucher Disease</keyword>
  <keyword>Thalassemia major</keyword>
  <keyword>Sickle cell disease (SCD)</keyword>
  <keyword>Diamond Blackfan Anemia (DBA)</keyword>
  <keyword>Crohn's Disease</keyword>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>IPEX or IPEX-like Syndromes</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Marrow Failure Disorders</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Congenital Bone Marrow Failure Syndromes</mesh_term>
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

